Trial · NCT01642082
Results by group227
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 227
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response | Dalantercept | 0 | 90% Confidence Interval 0 to 10.1 | percentage of participants | |
| Treatment and Progression-free Survival at 6 Months | Dalantercept | 10.7 | 90% Confidence Interval 3 to 25.4 | percentage of participants | |
| Progression-free Survival at 6 Months | Dalantercept | 17.9 | 90% Confidence Interval 7.3 to 33.9 | percentage of participants | |
| Duration of Progression-free Survival | Treatment (Dalantercept) | 2.1 | 90% Confidence Interval 1.4 to 3.2 | months | |
| Duration of Survival | Dalantercept | 14.5 | 90% Confidence Interval 7.0 to 17.5 | months | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 0 | Anemia | 13 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 1 (CTCAE v4.0) | Anemia | 5 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 2 (CTCAE v4.0) | Anemia | 8 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 3 (CTCAE v 4.0) | Anemia | 1 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 4 (CTCAE v 4.0) | Anemia | 1 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 5 (CTCAE v 4.0) | Anemia | 0 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 0 | Abdominal Distention | 24 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 1 (CTCAE v4.0) | Abdominal Distention | 2 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 2 (CTCAE v4.0) | Abdominal Distention | 2 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 3 (CTCAE v 4.0) | Abdominal Distention | 0 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 4 (CTCAE v 4.0) | Abdominal Distention | 0 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 5 (CTCAE v 4.0) | Abdominal Distention | 0 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 0 | Abdominal Pain | 20 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 1 (CTCAE v4.0) | Abdominal Pain | 6 | Participants | |
| Adverse Events (Primary Serious and All Other AEs) | Grade 2 (CTCAE v4.0) | Abdominal Pain | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01642082/results